Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Abstract Background Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20–30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy. Meth...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-02-01
|
| Series: | Journal of Translational Medicine |
| Online Access: | https://doi.org/10.1186/s12967-020-02231-0 |
| _version_ | 1818453710393573376 |
|---|---|
| author | Andrea Botticelli Pamela Vernocchi Federico Marini Andrea Quagliariello Bruna Cerbelli Sofia Reddel Federica Del Chierico Francesca Di Pietro Raffaele Giusti Alberta Tomassini Ottavia Giampaoli Alfredo Miccheli Ilaria Grazia Zizzari Marianna Nuti Lorenza Putignani Paolo Marchetti |
| author_facet | Andrea Botticelli Pamela Vernocchi Federico Marini Andrea Quagliariello Bruna Cerbelli Sofia Reddel Federica Del Chierico Francesca Di Pietro Raffaele Giusti Alberta Tomassini Ottavia Giampaoli Alfredo Miccheli Ilaria Grazia Zizzari Marianna Nuti Lorenza Putignani Paolo Marchetti |
| author_sort | Andrea Botticelli |
| collection | DOAJ |
| description | Abstract Background Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20–30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy. Methods The metabolomic profiling of gut microbiota was characterized in 11 patients affected by non-small cell lung cancer (NSCLC) treated with nivolumab in second-line treatment with anti-PD-1 nivolumab. The metabolomics analyses were performed by GC–MS/SPME and 1H-NMR in order to detect volatile and non-volatile metabolites. Metabolomic data were processed by statistical profiling and chemometric analyses. Results Four out of 11 patients (36%) presented early progression, while the remaining 7 out of 11 (64%) presented disease progression after 12 months. 2-Pentanone (ketone) and tridecane (alkane) were significantly associated with early progression, and on the contrary short chain fatty acids (SCFAs) (i.e., propionate, butyrate), lysine and nicotinic acid were significantly associated with long-term beneficial effects. Conclusions Our preliminary data suggest a significant role of gut microbiota metabolic pathways in affecting response to immunotherapy. The metabolic approach could be a promising strategy to contribute to the personalized management of cancer patients by the identification of microbiota-linked “indicators” of early progressor and long responder patients. |
| first_indexed | 2024-12-14T21:43:19Z |
| format | Article |
| id | doaj.art-99b3dbdf2f344f43b6e4967bf2f8b467 |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-12-14T21:43:19Z |
| publishDate | 2020-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-99b3dbdf2f344f43b6e4967bf2f8b4672022-12-21T22:46:24ZengBMCJournal of Translational Medicine1479-58762020-02-0118111010.1186/s12967-020-02231-0Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatmentAndrea Botticelli0Pamela Vernocchi1Federico Marini2Andrea Quagliariello3Bruna Cerbelli4Sofia Reddel5Federica Del Chierico6Francesca Di Pietro7Raffaele Giusti8Alberta Tomassini9Ottavia Giampaoli10Alfredo Miccheli11Ilaria Grazia Zizzari12Marianna Nuti13Lorenza Putignani14Paolo Marchetti15Department of Clinical and Molecular Medicine, Sapienza University of RomeUnit of Human Microbiome, Bambino Gesù Children’s Hospital, IRCCSDepartment of Chemistry, Sapienza University of RomeUnit of Human Microbiome, Bambino Gesù Children’s Hospital, IRCCSDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of RomeUnit of Human Microbiome, Bambino Gesù Children’s Hospital, IRCCSUnit of Human Microbiome, Bambino Gesù Children’s Hospital, IRCCSAOU Sant’Andrea HospitalAOU Sant’Andrea HospitalDepartment of Chemistry, Sapienza University of RomeDepartment of Chemistry, Sapienza University of RomeNMR-based Metabolomics Laboratory, Sapienza University of RomeDepartment of Experimental Medicine, University SapienzaDepartment of Experimental Medicine, University SapienzaUnit of Parasitology and Unit of Human Microbiome, Bambino Gesù Children’s Hospital, IRCCSDepartment of Clinical and Molecular Medicine, Sapienza University of RomeAbstract Background Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20–30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy. Methods The metabolomic profiling of gut microbiota was characterized in 11 patients affected by non-small cell lung cancer (NSCLC) treated with nivolumab in second-line treatment with anti-PD-1 nivolumab. The metabolomics analyses were performed by GC–MS/SPME and 1H-NMR in order to detect volatile and non-volatile metabolites. Metabolomic data were processed by statistical profiling and chemometric analyses. Results Four out of 11 patients (36%) presented early progression, while the remaining 7 out of 11 (64%) presented disease progression after 12 months. 2-Pentanone (ketone) and tridecane (alkane) were significantly associated with early progression, and on the contrary short chain fatty acids (SCFAs) (i.e., propionate, butyrate), lysine and nicotinic acid were significantly associated with long-term beneficial effects. Conclusions Our preliminary data suggest a significant role of gut microbiota metabolic pathways in affecting response to immunotherapy. The metabolic approach could be a promising strategy to contribute to the personalized management of cancer patients by the identification of microbiota-linked “indicators” of early progressor and long responder patients.https://doi.org/10.1186/s12967-020-02231-0 |
| spellingShingle | Andrea Botticelli Pamela Vernocchi Federico Marini Andrea Quagliariello Bruna Cerbelli Sofia Reddel Federica Del Chierico Francesca Di Pietro Raffaele Giusti Alberta Tomassini Ottavia Giampaoli Alfredo Miccheli Ilaria Grazia Zizzari Marianna Nuti Lorenza Putignani Paolo Marchetti Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment Journal of Translational Medicine |
| title | Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment |
| title_full | Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment |
| title_fullStr | Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment |
| title_full_unstemmed | Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment |
| title_short | Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment |
| title_sort | gut metabolomics profiling of non small cell lung cancer nsclc patients under immunotherapy treatment |
| url | https://doi.org/10.1186/s12967-020-02231-0 |
| work_keys_str_mv | AT andreabotticelli gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT pamelavernocchi gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT federicomarini gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT andreaquagliariello gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT brunacerbelli gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT sofiareddel gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT federicadelchierico gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT francescadipietro gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT raffaelegiusti gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT albertatomassini gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT ottaviagiampaoli gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT alfredomiccheli gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT ilariagraziazizzari gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT mariannanuti gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT lorenzaputignani gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment AT paolomarchetti gutmetabolomicsprofilingofnonsmallcelllungcancernsclcpatientsunderimmunotherapytreatment |